Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents

August 6, 2024 updated by: University of Florida

Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children

Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa. In addition, TDF/FTC is recommended for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection in adolescents at substantial risk of acquisition of HIV infection, as well as for hepatitis B virus (HBV) treatment in those with HBV/HIV coinfection. The efficacy TDF and FTC are dependent on intracellular concentrations of the active phosphate anabolites, called TFV diphosphate (TFV-DP) and FTC triphosphate (FTC-TP). However, the intracellular pharmacokinetics of TFV-DP and FTC-TP to examine the adequacy of current dosages in African adolescents has not been previously studied. Thus, examining the pharmacokinetics (PK) of these widely used antiretrovirals in African adolescents is important as ART outcomes remain poor and the recommended dosages of these drugs for children and adolescent were extrapolated from drug approval clinical trials in adult in the United States and Europe.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study will evaluate the intracellular PK of TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents with and without TB coinfection. As the clinical effects of TDF and FTC are related to the intracellular concentrations of the phosphate anabolites, called TFV-DP and FTC-TP, there is a need to understand the cellular pharmacology of TDF interactions in African HIV-infected adolescents with and without TB, as the study team cannot extrapolate from US patients not on antituberculosis (anti-TB) drugs. This study will enroll HIV-infected adolescents aged 10 to 18 years old with and without TB coinfection who are already established on ART. The study team hypothesize that younger age, adenosine triphosphate (ATP)-binding cassette subfamily C (ABCC) single nucleotide polymorphisms (SNPs) and anti-TB therapy may influence the intracellular TFV-DP and FTC-TP concentrations in adolescents.

Study Type

Observational

Enrollment (Actual)

52

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Oluwayemisi Ojewale, MBChB, MPH
  • Phone Number: 3522739446
  • Email: oawoyemi@ufl.edu

Study Locations

      • Kumasi, Ghana
        • Kwame Nkrumah University of Science and Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 19 years (Child, Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adolescents aged 10-19 years with HIV with or without TB co-infection.

Description

Inclusion Criteria:

  • HIV-infected adolescents aged 10 to 19 years old who are stable on antiretroviral regimen containing TDF/FTC (300/200 mg daily) for at least 8 weeks.

Exclusion Criteria:

  • Unable to obtain informed signed consent from parent(s) or legal guardian.
  • Pregnant or breast feeding.
  • Require therapy for other opportunistic infections other than tuberculosis (TB).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
HIV only
Adolescents aged 10-19 years with HIV infection
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
HIV/TB
Adolescents aged 10-19 years with HIV and TB coinfection
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average concentration (Cav) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
Mean and median Cav of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
After at least 8 weeks of HIV therapy.
Area under the time-concentration curve 0-24 hours (AUC0-24h) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
Mean and median AUC0-24h of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
After at least 8 weeks of HIV therapy.
Cav of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.
Time Frame: After at least 8 weeks of HIV therapy.
Geometric mean intracellular TFV-DP and FTC-TP Cav in adolescents with TB/HIV coinfection compared to those only HIV infection.
After at least 8 weeks of HIV therapy.
AUC0-24h of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.
Time Frame: After at least 8 weeks of HIV therapy.
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents with TB/HIV coinfection compared to those with only HIV infection.
After at least 8 weeks of HIV therapy.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effect of age on TFV-DP and FTC-TP Cav.
Time Frame: After at least 8 weeks of HIV therapy.
Geometric mean of intracellular TFV-DP and FTC-TP Cav in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.
After at least 8 weeks of HIV therapy.
Effect of age on TFV-DP and FTC-TP AUC0-24h .
Time Frame: After at least 8 weeks of HIV therapy.
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.
After at least 8 weeks of HIV therapy.
Intracellular TFV-DP and FTC-TP Cav in adolescents compared to that in historical adult controls.
Time Frame: After at least 8 weeks of HIV therapy.
Geometric mean of intracellular TFV-DP and FTC-TP Cav in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.
After at least 8 weeks of HIV therapy.
Intracellular TFV-DP and FTC-TP AUC0-24h in adolescents compared to that in historical adult controls.
Time Frame: After at least 8 weeks of HIV therapy.
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.
After at least 8 weeks of HIV therapy.
Relationship between Adenosine triphosphate (ATP)-binding cassette subfamily C, member 2 (ABCC2), member 4 (ABCC4) and member 10 (ABCC10) SNPs and TFV-DP and FTC-TP AUC0-24h.
Time Frame: After at least 8 weeks of HIV therapy.
Relationship between ABCC2, ABCC4 and ABCC10 SNPs and intracellular TFV-DP and FTC-TP AUC0-24h.
After at least 8 weeks of HIV therapy.
Prevalence and covariates of intracellular TFV-DP Cav < 95 fmol/106 cells in adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
Proportion of Ghanaian adolescents and factors associated with intracellular TFV-DP average concentration < 95 fmol/106 cells.
After at least 8 weeks of HIV therapy.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Awewura Kwara, MD, University of Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 28, 2019

Primary Completion (Actual)

May 31, 2024

Study Completion (Actual)

July 31, 2024

Study Registration Dates

First Submitted

January 3, 2019

First Submitted That Met QC Criteria

January 8, 2019

First Posted (Actual)

January 11, 2019

Study Record Updates

Last Update Posted (Actual)

August 7, 2024

Last Update Submitted That Met QC Criteria

August 6, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • IRB201801820 - PKAdol
  • 2R01HD071779 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.